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Histone H2A.Z (H2A.Z) is an evolutionarily conserved H2A variant implicated in the regulation of gene expression;
however, its role in transcriptional deregulation in cancer remains poorly understood. Using genome-wide studies, we
investigated the role of promoter-associated H2A.Z and acetylated H2A.Z (acH2A.Z) in gene deregulation and its re-
lationship with DNA methylation and H3K27me3 in prostate cancer. Our results reconcile the conflicting reports of
positive and negative roles for histone H2A.Z and gene expression states. We find that H2A.Z is enriched in a bimodal
distribution at nucleosomes, surrounding the transcription start sites (TSSs) of both active and poised gene promoters. In
addition, H2A.Z spreads across the entire promoter of inactive genes in a deacetylated state. In contrast, acH2A.Z is only
localized at the TSSs of active genes. Gene deregulation in cancer is also associated with a reorganization of acH2A.Z and
H2A.Z nucleosome occupancy across the promoter region and TSS of genes. Notably, in cancer cells we find that a gain of
acH2A.Z at the TSS occurs with an overall decrease of H2A.Z levels, in concert with oncogene activation. Furthermore,
deacetylation of H2A.Z at TSSs is increased with silencing of tumor suppressor genes. We also demonstrate that acH2A.Z
anti-correlates with promoter H3K27me3 and DNA methylation. We show for the first time, that acetylation of H2A.Z is
a key modification associated with gene activity in normal cells and epigenetic gene deregulation in tumorigenesis.
[Supplemental material is available for this article.]
Epigenetics involves the understanding of chromatin structure
and its impact on the regulation of gene expression. Epigenetic
mechanisms that modify chromatin structure include DNA
methylation, histone post-synthetic modifications, nucleosome
positioning, incorporation of histone variants into nucleosomes
and expression of noncoding RNAs. The basic repeating unit of
chromatin is the nucleosome, a particle consisting of an octamer of
core histones (two copies each of histones H2A, H2B, H3, and H4),
around which ;146 bp of DNA is wrapped (Sharma et al. 2010).
Both the modification of histones and incorporation of histone
variants into nucleosomes have been described to modulate
chromatin structure (Kamakaka and Biggins 2005; Campos and
Reinberg 2009). H2A.Z is an evolutionary conserved variant of the
canonical histone H2A (H2A), which shares only ;60% sequence
identity with major H2A, and is required for viability in metazoans,
suggesting a unique function (Faast et al. 2001; Zlatanova and
Thakar 2008) In fact, H2A.Z occupancy has been involved in
contrary and varying functions in different species, including both
gene activation (Barski et al. 2007) and gene silencing (Gevry
et al. 2007), nucleosome turnover (Santisteban et al. 2000), DNA
repair (Rong 2008), heterochromatin silencing (Rangasamy et al.
2003), chromosome segregation (Rangasamy et al. 2004), pro-
gression through the cell cycle (Dhillon et al. 2006), suppression of
antisense RNAs (Zofall et al. 2009), embryonic stem cell differenti-
ation (Creyghton et al. 2008), and antagonizing DNA methylation
(Zilberman et al. 2008).
Recently, ChIP and tiling microarray technologies have pro-
vided high-resolution genome-wide information that has localized
H2A.Z to the promoters of many genes in several organisms in-
cluding humans, which suggests a role in gene transcription
(Barski et al. 2007). However, the precise function of H2A.Z in
transcriptional regulation is still poorly understood and may differ
between species (Guillemette and Gaudreau 2006). In human T
cells, promoter enrichment of H2A.Z is often associated with ac-
tively expressing genes (Barski et al. 2007); however, independent
studies show that H2A.Z can also be found at particular promoters
of inducible genes, where it functions to repress expression (Gevry
et al. 2007; Sutcliffe et al. 2009). Thus, deposition of H2A.Z at the 59
end of genes may act to set up chromatin architecture that is com-
patible with gene-specific regulation and suggests that it might
regulate both transcriptional silencing and activation via different
mechanisms (Marques et al. 2010).
H2A.Z occupancy may also influence other histone compo-
nents within the nucleosome that mediate different downstream
functions in transcriptional regulation. For example, H2A.Z and
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H3K27me3 are colocalized at genes with low-expression levels in
embryonic stem (ES) cells, suggesting a role in potentiating gene
expression (Creyghton et al. 2008). In addition, loss of H2A.Z in
Drosophila and mammals (Greaves et al. 2007) suppresses hetero-
chromatin formation, suggesting a role in gene suppression. H2A.Z
occupancy also has been reported in plants to protect genes from
DNA methylation (Zilberman et al. 2008), and this anticorrelation
has now been further demonstrated in the puffer fish (Zemach
et al. 2010) and in murine B-cells (Conerly et al. 2010).
Similar to other histones, H2A.Z is also subject to modification,
including multiple N-terminal acetylation in Saccharomyces cerevisiae
(Millar et al. 2006), Tetrahymena thermophila (Ren and Gorovsky 2001),
and metazoans (Bruce et al. 2005). In yeast the H2AZ acetylation levels
correlate with genome-wide gene activity (Millar et al. 2006) and is
required for induction of gene transcription (Halley et al. 2010). In
addition, studies in chicken erythroblast cells found that the hyper-
acetylated form of H2A.Z (K4, K7, and K11) (acH2A.Z) is concentrated
at the 59 end of active genes (Bruce et al. 2005) and confers nucleosome
destabilization and an open conformation (Ishibashi et al. 2009).
Recently, a role for H2A.Z in gene deregulation in cancer has
been suggested. The depletion of H2A.Z affects the stability and
integrity of the human genome, causing the alteration of chro-
mosome segregation (Rangasamy et al. 2004) and changes in cell
cycle (Gevry et al. 2009b). A progressive depletion of H2A.Z around
the transcriptional start sites (TSSs) during B-cell lymphoma-
genesis in the mouse has also been reported (Conerly et al. 2010).
In contrast, the activation of LINE-1 transposable elements corre-
lates with an acquisition of H2A.Z around the TSS (Wolff et al.
2010). Furthermore, H2AFZ gene expression is increased in several
human malignancies including colorectal cancer, undifferentiated
cancers, and breast cancer (Dunican et al. 2002; Rhodes et al. 2004;
Zucchi et al. 2004) and also at the protein level in the case of breast
cancer ( Hua et al. 2008). However, the role of H2A.Z and acetylated
H2A.Z in epigenetic associated deregulation of gene expression in
human cancer has not been addressed.
To explore the relationship between gene expression, H2A.Z/
acH2A.Z promoter occupancy, and the epigenetic repressive marks
of DNA methylation and H3K27me3 in human cancer, we per-
formed ChIP-on-chip (for histone marks) and MBDCap.seq (for DNA
methylation) to characterize the epigenetic landscape in normal and
prostate cancer cells. We found that while H2A.Z was associated with
both active and inactive gene promoters, acH2A.Z was specific only
for actively transcribed genes. Notably, in the cancer cells acetylation
of H2A.Z was associated with oncogene activation and deacetylation
was associated with silencing of tumor-suppressor genes (TSG).
Furthermore, correlation analyses show a mutually exclusive occu-
pancy of acH2A.Z and the repressive marks, DNA methylation and
H3K27me3. The observed remodeling of promoter-associated H2A.Z
and acH2A.Z with cancer-specific gene deregulation implicates a key
role for the histone variant H2A.Z in tumorigenesis.
Results
H2A.Z is localized at transcription start sites of both poised
and actively expressed genes
To determine the relationship between gene activity and distribution
of H2A.Z within gene promoters in cancer and normal cells, we
compared gene expression (Affymetrix GeneChip HuGene 1.0ST ar-
rays) and H2A.Z ChIP-on-chip (Affymetrix Human Promoter 1.0 ar-
rays) analyses, in normal prostate epithelial cells (PrEC), and the
prostate cancer cell line LNCaP. We found that in both PrEC (Fig. 1A)
and LNCaP (Supplemental Fig. 1A), the distribution of H2A.Z
around TSSs differs substantially in relation to gene transcription. In
inactive genes, (25% of genes, defined as expression levels RMA <4.5,
see Supplementary Methods), H2A.Z was uniformly distributed
across the entire promoter region (from 7500 bp to +2450 bp). In
contrast, genes that were transcribed, either at poised or basal levels
(expression levels 4.5–6, 25%) or medium or high levels (expression
levels >6, 50%), were associated with a bimodal redistribution of
H2A.Z, enriched at nucleosomes surrounding TSSs, between1500-
bp and +1000-bp regions, as previously described (Barski et al. 2007).
Notably, we found that the intensity of the H2A.Z peak, located at
;500 bp upstream of TSSs, was diminished with decreasing levels of
gene expression transcription. In contrast, the second H2A.Z peak,
located ;500 bp downstream from TSSs, did not show significant
enrichment differences in relation to gene expression. Interestingly,
genes with high expression exhibit a relative loss of H2A.Z imme-
diately after TSSs (between 0 and 250 bp). This region could corre-
spond to a nucleosome-depleted region (NDR) (Ozsolak et al. 2007;
Schones et al. 2008); however, we found that the relative depletion
of histone H3 (H3) was more pronounced from +1000 to +2000 bp
from TSSs in the most highly expressed genes (Supplemental Fig.
1B); a finding consistent with previous published data (Barski et al.
2007; Hardy et al. 2009; Zemach et al. 2010), suggesting that loss of
nucleosomes at the TSS may not be the sole reason for the apparent
bimodal promoter distribution of H2A.Z.
H2A.Z enrichment correlates with H2A depletion in actively
transcribed genes
H2A.Z can assemble into either homotypic nucleosomes (consisting
of H2A.Z–H2B tetramers) or heterotypic nucleosomes (consisting of
one H2A.Z–H2B dimer and one H2A–H2B dimer), each having dif-
ferent effects on chromatin remodeling and transcription (Suto et al.
2000; Chakravarthy et al. 2004; Ishibashi et al. 2009; Weber et al.
2010). To investigate whether H2A.Z/H2A exchange is another po-
tential epigenetic-based mechanism for gene transcriptional (de)-
regulation, we determined the relative differences in H2A.Z and
H2A occupancy at gene promoters according to expression levels in
LNCaP and PrEC cells. Heatmap analysis of the H2A ChIP-on-chip
data revealed that in both normal prostate PrEC (Fig. 1B) and cancer
LNCaP cells (Supplemental Fig. 1C), there was a bimodal depletion
of H2A spanning TSSs in the highly expressed genes. Notably, de-
pleted H2A regions inversely correspond to regions showing bi-
modal enrichment of H2A.Z with increasing gene expression (see
gene examples in Supplemental Fig. 2A). In contrast, we observed
intermediate levels of both H2A and H2A.Z in the poorly transcribed
and silent genes (Fig. 1A,B; see gene examples in Supplemental Fig.
2B). These results suggest that while the presence of homotypic
H2A.Z nucleosomes are assembled around the TSS of actively tran-
scribed genes, (Weber et al. 2010; Supplemental Fig. 2A,C), hetero-
typic nucleosomes (consisting of both H2A and H2A.Z) or a mix of
both homotypic H2A-nucleosomes and H2A.Z-nucleosomes, might
occur across inactive genes (Supplemental Fig. 2B,C).
Acetylation of H2A.Z is a key modification at promoters
of highly expressed genes
It has previously been shown in chicken that H2A.Z can be
acetylated at specific lysines (Sarcinella et al. 2007; Ishibashi et al.
2009), and both the presence of H2A.Z and its acetylation form
is associated with gene activation. We therefore determined
whether acetylation of H2A.Z was also correlated with active gene
2 Genome Research
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expression in the prostate normal and cancer cells. Using an an-
tibody specific for acH2A.Z (Bruce et al. 2005), we found that
acetylation of H2A.Z was restricted to the proximal promoters of
only the active genes (expression levels >6, 50% of the genes) in
both normal (Fig. 1C) and cancer cell lines (Supplemental Fig.
1D). For H2A.Z, there was a bimodal distribution observed around
the TSS, but with more pronounced enrichment with increasing
with gene expression levels (expression levels >6); which was further
augmented when acH2A.Z was normalized to the levels of total
H2A.Z (comprising both the acetylated and underacetylated forms;
see Supplemental Methods; Fig. 1D; Supplemental Fig. 1E). How-
ever, unlike H2A.Z distribution, there was a clear lack of acH2A.Z in
both the poised/lowly expressed genes (expression levels 4.5–6, 25%
of the genes) and inactive genes (expression levels <4.5, 25%) (Fig.
1C,D; Supplemental Fig. 1C,D). Notably, the acH2A.Z profiles, rel-
ative to gene expression, were similar to the profiles of the active
chromatin marks H3K9 acetylation (H3K9ac) and H3K4 trimethy-
lation (H3K4Me3) (Bernstein et al. 2005); with a similar bimodal
distribution across the TSSs of active genes, but dissimilar to the
repressive H3K27 trimethylation (H3K27me3) chromatin mark that
is depleted across the entire gene promoter of active genes (Sup-
plemental Fig. 3).
Acetylation of H2A.Z is correlated with gene deregulation
in prostate cancer
We next investigated the role of H2A.Z and its post-translational
modification in deregulation of gene expression in prostate
cancer. First, we compared the changes of H2A.Z occupancy along
the promoter of genes that were deregulated in LNCaP cancer
cells relative to PrEC (Fig. 2A). In LNCaP cells, we observed a sig-
nificant relocalization of H2A.Z downstream from the TSS, in-
cluding part of gene bodies (from +1000 bp to +2450 bp), with
a gain of H2A.Z in the most repressed genes and loss of H2A.Z in
the most activated genes. However around TSSs, we observed
a minor depletion of H2A.Z, primarily in actively transcribed
genes (Fig. 2A). We also observed a moderate increase in H2A
occupancy from 4000 bp in the down-regulated genes (Fig. 2B),
but no other H2A or H2A.Z changes were found across promoters
of deregulated genes. Next, we investigated whether acH2A.Z was
associated with transcriptional deregulation in LNCaP cells and
analyzed levels of absolute acH2A.Z (Fig. 2C) and relative acH2A.Z
(acH2A.Z/H2A.Z) along the entire promoter regions (Fig. 2D). We
found that the most down-regulated genes (blue line) exhibited
a loss of both acH2A.Z and acH2A.Z/H2A.Z along the entire
Figure 1. Correlation between gene expression and H2A.Z, H2A, acH2A.Z promoter occupancy in PrEC cells. Heatmaps (left) showing levels of H2A.Z
(A), H2A (B), acH2A.Z (C ), and acH2A.Z/H2A.Z (D) across gene promoters according to gene expression in PrEC. The x-axis represents promoter co-
ordinates (7500 bp to +2450 bp), where 0 is the transcriptional start site (TSS). Each row of the y-axis represents the average H2A.Z (A), H2A (B), acH2A.Z
(C ), and acH2A.Z/H2A.Z (D) signal intensity of 500 genes ordered according to gene expression levels (right), using robust multichip analysis (RMA).
Antibody signal intensity (using MAT normalization) is represented from blue (low signal) to red (high signal). AcH2A.Z/H2A.Z represents acH2A.Z
normalized with H2A.Z total levels. Black dotted lines demark genes either inactive (RMA < 4.5, 25% of the genes), or transcribed, either at basal levels
(RMA 4.5–6, 25%) or medium or high levels (RMA > 6, 50%). Line plots (right) for H2A.Z (A), H2A (B), acH2A.Z (C ), and acH2A.Z/H2A.Z (D) show
enrichment in PrEC according to different levels of expression. Gene expression levels were split in groups of 2500 genes (blue for low expressed genes;
green to red for high expressed genes). The average signal of the specific group was plotted along the gene promoter.
Acetylation of H2A.Z is deregulated in cancer
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promoter, indicating that either deacetylation or lack of reacet-
ylation occurs with gene inactivation. Conversely, in the most
up-regulated cancer genes (red line), levels of absolute acH2A.Z
exhibited a gain from 3000 bp to the TSS, whereas the level of
relative acH2A.Z exhibited a stronger signal with two discrete
peaks of gain around TSSs.
Exchange between H2A.Z and acH2A.Z-containing
nucleosomes in prostate cancer
We have demonstrated that acH2A.Z levels are tightly associated
with an increase in transcriptional activity and vice versa in pros-
tate cancer. Conversely, H2A.Z is reorganized at gene promoters
according to transcriptional levels; however, this mechanism ap-
pears independent of gene deregulation. Given that, unlike H3,
H2A.Z is not constant among gene promoters, we wanted to further
analyze whether differential levels of acH2A.Z/H2A.Z could result
from differential distribution of acH2A.Z and H2A.Z. A gene list was
created of the most up-regulated genes (25% of the genes) (Fig. 3A,
red line) and down-regulated genes (25% of the genes) (Fig. 3A, blue
line) in LNCaP cells. Of the 2153 overexpressed genes, 1552 (72%)
had increased acH2A.Z/H2A.Z levels in LNCaP (levels of acH2A.Z/
H2A.Z presence using two-sided t-test, t-stats > 0). Of the 2110 down-
regulated genes, 1391 (65%) genes had a loss of acH2A.Z/H2A.Z
(t-stats > 0). We then selected from the overexpressed list, the genes
with the highest levels of acH2A.Z/H2A.Z (545 genes, acH2A.Z/
H2A.Z t-stats $ 1.5; Supplemental Table 1) and those that had the
greatest loss of acH2A.Z/H2A.Z (479 genes t-stats # 1.5; Supple-
mental Table 2). We found that the 479 down-regulated cancer genes
showing a loss of acH2A.Z/H2A.Z (Fig. 3B, blue boxes, ‘‘Down’’),
exhibited a significant gain of H2A.Z and concurrent loss of acH2A.Z
across the promoter (2000 bp to +1500) region, suggesting that
H2A.Z deacetylation is predominately associated with gene repres-
sion in prostate cancer cells. Figure 3C shows screen shots of repre-
sentative gene promoter examples including NFKB1, SERPINB5, and
ANXA1. These findings indicate that gene repression in cancer is not
a result of a total loss of H2A.Z, but a loss of acH2AZ. This suggests
that genes that exist in a poised state could potentially be reactivated
by acetylation of H2A.Z. Conversely, in the up-regulated genes that
show a gain of acH2A.Z/H2A.Z (Fig. 3B, red boxes, ‘‘Up’’) we found
a significant loss of H2A.Z and a gain of acH2A.Z, suggesting that
promoter-associated H2A.Z is predominately acetylated in activated
Figure 2. H2A.Z, H2A, and acH2A.Z occupancy changes with gene deregulation in prostate cancer. Heatmaps (left) and line plots (right) for H2A.Z (A),
H2A (B), acH2A.Z (C ), and acH2A.Z/H2A.Z (D) were made according to changes in gene expression in LNCaP relative to PrEC (LNCaP-PrEC), represented
as a moderated t-statistics (T-stats), to study nucleosome occupancy with changes in gene expression. For heatmaps, genes were sorted into groups of 500
genes, according to changes in gene expression in LNCaP-PrEC, from down-regulated (bottom) to up-regulated (top). The color scale represents changes
in signal intensity of each antibody (using a two-sided t-test), between LNCaP and PrEC from blue (loss of signal) to red (gain of signal). For line plots,
groups of 2500 genes were generated according to changes in gene expression in LNCaP-PrEC. The y-axis represents the average change in each antibody
between LNCaP and PrEC. Line colors are as described for Figure 1.
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Figure 3. Opposing changes in H2A.Z and acH2A.Z occupancy is a potential mechanism of transcriptional (de)regulation. (A) Line plots of acH2A.Z/
H2A.Z changes in LNCaP compared to PrEC. Top 25% up-regulated genes (red line) and top 25% down-regulated genes (blue line), across the promoter
region, 2000 bp to +1500 bp highlighted in hatched boxes. ‘‘Up’’: top up-regulated genes show a gain of acH2A.Z /H2A.Z. ‘‘Down’’: top down-
regulated genes show a loss of acH2A.Z/H2A.Z. (B) Box plots display the significance of change between H2A.Z and acH2A.Z levels. y-axis: distributions of
t-statistics (H2A.Z and acH2A.Z) with change in expression. x-axis: ‘‘NC’’ (no change in expression, gray boxes); ‘‘Down’’ (down-regulated genes, blue
boxes); ‘‘Up’’ (up-regulated genes, red boxes). The P-values of significance of differences between box plots were obtained with the limma function
geneSetTest where (*) means a P-value of <0.05. (C ) (Top) Microarray hybridization signals for mRNA expression levels in LNCaP (red) and PrEC (green) of
three representative oncogenes from Table 1 (left), and three tumor suppressor genes (TSG) from Table 2 (right). Gray background highlights signals
below detection (<5.0). UCSC Genome Browser tracks (bottom) for H2A.Z (green background), acH2A.Z (yellow background), and acH2A.Z/H2A.Z (gray
background). Enrichment over input status and differential pattern shown. Pr (green tracks): PrEC; LN (red tracks): LNCaP; LN-Pr (black tracks): LNCaP
minus PrEC. TSS for each gene shown as an arrow, genomic coordinates are indicated and CpG islands are depicted by green boxes. The scale of UCSC
tracks is represented as the distance in kilobases (kb) upstream of ‘‘’’ and downstream from ‘‘+‘‘ the TSS.
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prostate cancer genes. Figure 3C shows screen shots of representative
gene examples including CDK4, LCP1, and RASEF.
Prostate cancer oncogenes and tumor-suppressor genes
have altered acH2A.Z /H2A.Z promoter occupancy
We next identified known key genes involved in carcinogenesis that
exhibited altered expression in LNCaP cells to determine whether
the change in acH2A.Z/H2A.Z promoter levels are associated with
their transcriptional alteration. Table 1 summarizes a subset of genes
from Supplemental Table 1 that are reported oncogenes in prostate
cancer, including KLK2, C15orf21, and ERBB3 (Futreal et al. 2004)
(http://www.sanger.ac.uk/genetics/CGP/Census/). Table 2 summa-
rizes a subset of genes from Supplemental Table 2 that are reported
TSG in prostate cancer, including CAV1, CAV2, and RND3 (Higgins
et al. 2007) (http://cbio.mskcc.org/CancerGenes/Select.action). We
validated the change in expression and H2A.Z and acH2A.Z pro-
moter level occupancy of three up-regulated oncogenes (KLK2,
C15orf21, and ERBB3) and three down-regulated TSG (CAV1, CAV2,
and RND3) in LNCaP and PrEC cells from the gene expression and
ChIP-on-chip data (Fig. 4A). We confirmed in prostate cancer cells
by qRT–PCR (Fig. 4B), that gene activation or repression was in-
versely correlated with acetylation or deacetylation of H2A.Z, re-
spectively, with the exception of the ERBB3 gene. Furthermore,
treatment of LNCaP cells with the deacetylase inhibitor Trichostatin
A (TSA) results in concordant gene activation and gain of the
acH2A.Z mark across the TSS of repressed genes, (for example, CAV1
and CAV2) (Fig. 5A). In addition, active genes (for example LIMCH1,
KLK2, and KLK3) can be further activated after TSA treatment, in
association with an increase in acetylation of H2A.Z (Fig. 5B).
Conversely, LNCaP cells treated with Anarcardic Acid (AA), an in-
hibitor of histone acetyl transferases (HATs) (Balasubramanyam
et al. 2003) resulted in deacetylation of H2A.Z and consequent
transcriptional repression of genes that harbor high levels of
acH2AZ at gene promoters such as KLK2, C15orf21, and KLK3 (Fig.
5C). This data combined supports a potential mechanistic link be-
tween the acetylation status of H2A.Z and active gene transcription.
We have also validated the direct association between changes in
acH2A.Z and changes in gene expression in two additional prostate
cancer cell lines PC-3 and DU-145, demonstrating that the associ-
ation is not cell line dependent (Fig. 5D).
H2A.Z and acH2A.Z nucleosome occupancy is anticorrelated
with DNA methylation in cancer cells
Next we determined whether there was an inverse relationship
between H2A.Z and acH2A.Z occupancy and DNA methylation in
prostate cancer cells, as H2A.Z occupancy has been reported
(Zilberman et al. 2008; Conerly et al. 2010; Zemach et al. 2010) to be
antagonistic to DNA methylation. We compared the DNA methyl-
ation profile of PrEC and LNCaP cells, using MBDCap.seq, with
H2A.Z and acH2A.Z ChIP-on-chip data (Fig. 6A). We found a sig-
nificant correlation between highly methylated genes (red line) and
low H2A.Z and acH2A.Z occupancy around the TSS in both nor-
mal and cancer cells. Conversely, genes that are lowly or com-
pletely unmethylated (black line) have a significant increase in
H2A.Z and acH2A.Z levels. Interestingly, the opposite pattern was
observed for H2A deposition, where H2A nucleosomes positively
correlated with high levels of DNA methylation, whereas genes
poorly methylated were depleted in H2A associated nucleosomes
(Supplemental Fig. 4).
We next asked whether genes that became either hyper- or
hypomethylated in LNCaP cells, compared with PrEC cells, also
underwent a concordant change in the H2A.Z modification. Genes
were plotted according to promoter hypermethylation in the cancer
cell ($2-fold more methylated in LNCaP than PrEC, 3150 genes; see
Supplemental Methods) or hypomethylation ($2-fold less methyl-
ated in LNCaP than PrEC, 225 genes). A trend was observed for gain
of acH2A.Z in hypomethylated genes, but no significant anti-
correlation between DNA methylation and H2A.Z nor acH2A.Z
occupancy was found (Supplemental Fig. 5). To test the hypothesis
that an anticorrelation only occurred in gene promoters that
changed in cancer-associated gene expression, we sorted the gene
lists according to changes in DNA methylation and gene expression.
We found that 903 hypermethylated genes exhibited significant
gene silencing (expression t-stats # 1.5) and 75 hypomethylated
genes were activated (expression t-stats $ 1.5) in the cancer cells
(Supplemental Tables 3, 4). Using this criteria, a significant anti-
Table 1. Oncogenes associated with a loss of acH2A.Z/H2A.Z
Gene
symbol
T-stats
expression
T-stats
diff H2A.Z
(2000 to +1500 bp)
T-stats
diff acH2A.Z
(2000 to +1500 bp)
T-stats diff
acH2A.Z/H2A.Z
(2000 to +1500 bp)
Fold
change MBDCap
(2000 to +1500 bp)
T-stats
diff K27me3
(1000 to +1000 bp)
Oncogene
in prostate
cancer (PC)
KLK2 16.67 0.62 6.81 5.74 1.36 5.36 PC
CDK4 3.20 2.60 1.43 3.09 2.99 0.18
IDH1 5.66 3.68 0.47 2.70 3.33 0.19
HLF 9.68 1.05 2.75 2.53 2.97 3.41
C15orf21 5.64 0.39 4.55 2.44 0.33 4.15 PC
LCP1 4.42 1.93 1.35 2.23 0.41 2.58
BCL6 7.68 2.99 0.75 2.14 0.30 0.66
IDH2 7.07 2.84 0.50 2.13 2.79 1.05
PRCC 3.37 0.48 3.48 2.01 0.55 0.59
GPC3 8.20 1.29 1.10 1.65 1.02 2.33
NCOA2 3.87 2.51 0.34 1.58 3.29 1.06
RASEF 10.10 2.15 1.43 2.81 0.85 2.04
CASC4 4.77 2.77 0.28 2.71 0.78 0.33
ERBB3 7.33 0.96 2.38 2.61 0.00 0.07 PC
AFF3 14.69 1.00 4.85 2.28 1.64 5.48
RAB3B 5.17 0.94 1.05 1.64 1.59 1.92
FRAT1 3.24 0.53 2.12 1.60 1.91 1.62
Sanger and Cbio MSKCC resources. Shaded rows: Oncogene reported in prostate cancer.
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correlation was observed only for acH2A.Z, but not for H2A.Z (Fig.
6B). We validated the inverse relationship between acH2A.Z and
DNA methylation and expression using qRT–PCR, acH2A.Z, and
H2A.Z ChIP qPCR and Sequenom methylation analysis (Coolen
et al. 2007) on three genes (MKRN3, LIMCH1 and RND3) from Table
2 and Supplemental Table 4 that showed changes in methylation
(Fig. 6C; Supplemental Fig. 6). In addition, we previously described
changes in DNA methylation of CAV1 and CAV2 genes between
LNCaP and PrEC cells (Coolen et al. 2010), which also confirmed
this mutual exclusion. Together, this data supports the conclusion
that it is the acetylation of H2A.Z that is anticorrelated with DNA
methylation and gene activity and not H2A.Z itself. Our results
suggest an epigenetic mechanistic link where deregulated genes in
prostate cancer present opposite changes between DNA methyla-
tion and the acetylation state of H2A.Z.
H2A.Z and acH2A.Z promoter presence is anticorrelated
with H3K27me3
H2A.Z and H3K27me3 are enriched at genes with low-expression
levels in ES cells, although this pattern is not maintained in multi-
potent neural precursors (Creyghton et al. 2008). In order to study
the relationship between H2A.Z and the polycomb mark, we com-
pared H2A.Z and acH2A.Z with H3K27me3 ChIP-on-chip data.
H2A.Z and acH2A.Z status was filtered in two groups: H2AZ or
acH2A.Z high (t-stats > 1.5) and low (t-stats < 1.5), where the
K27Me3 ChIP-on-chip average signal was plotted along promoter
region in PrEC and LNCaP (Fig. 7A). Consistent with previous data
demonstrating H2A.Z and acH2A.Z as an active chromatin mark
surrounding the TSS, we observed a significant anticorrelation be-
tween K27Me3 and H2A.Z, acH2A.Z, and acH2A.Z/H2A.Z (Fig. 7A).
The same criteria were established to study whether this anti-
correlation occurs in the cancer cells, which could suggest a relevant
role in gene deregulation during prostate cancer development and
progression. Figure 7B shows a significant anticorrelation between
the polycomb mark H3K27Me3 and acH2A.Z and acH2A.Z/H2A.Z,
but not for H2A.Z. We confirm this anticorrelation in prostate
cancer for CAV1, RND3, KLK2 and LIMCH1 by qPCR (Fig. 7C). In
LNCaP cells, CAV1 and RND3 genes were enriched in H3K27Me3
(Fig. 7C) in the same region that acH2A.Z/H2A.Z is lost (Fig. 4B). In
addition, KLK2 and LIMCH1 genes showed decreased H3K27Me3
levels (Fig. 7C), whereas acH2A.Z/H2A.Z is increased in LNCaP cells
(Figs. 4B, 7C). We conclude that the anticorrelation between
acH2A.Z and H3K27Me3 might also play a critical role in the de-
regulation of gene expression in prostate cancer.
Discussion
A new epigenetic H2A.Z acetylation model for the regulation
of transcription
The role of the histone variant H2A.Z in epigenetically regulated
gene expression remains controversial with conflicting reports of its
role in both active and inactive gene expression in different model
systems. In this study, we characterized the nucleosome occupancy
of H2A.Z and acetylation status in human gene promoters to de-
termine its role in epigenetic remodeling and gene deregulation in
prostate cancer cells. We found that the landscape of H2A.Z pro-
moter occupancy and its acetylation state directly correlates with
the level of gene expression, arguing that acetylation of H2A.Z plays
a key role in gene regulation in normal cells and gene deregulation
in cancer. Figure 8 summarizes our data in a model where we find
Table 2. Tumor suppressor genes associated with a loss of acH2A.Z/H2A.Z
Gene
symbol
T-stats
expression
T-stats
diff H2A.Z
(2000 to +1500 bp)
T-stats
diff acH2A.Z
(2000 to +1500 bp)
T-stats
diff acH2A.Z/H2A.Z
(2000 to +1500 bp)
Fold
change MBDCap
(2000 to +1500 bp)
T-stats
diff K27me3
(1000 to +1000 bp)
TSG in
prostate
cancer (PC)
INHBA 9.59 2.00 3.57 4.13 4.78 1.97
CAV1 23.80 0.41 4.35 3.73 1.68 4.77 PC
CLCA2 13.24 1.83 9.27 3.55 0.72 1.55
SFN 21.09 2.83 1.87 3.36 9.43 1.03 PC
IL1B 16.39 0.32 4.32 3.28 0.41 0.82
TP63 18.58 0.89 3.33 3.08 2.94 1.30 PC
CAV2 28.24 1.17 3.22 3.05 5.67 1.75 PC
CDKN1A 3.51 3.19 0.57 2.95 0.88 1.13 PC
AIFM2 3.63 0.10 4.10 2.81 3.95 0.98
NFKB1 3.21 1.78 1.97 2.72 0.39 1.51 PC
JUP 4.90 1.73 1.43 2.42 0.00 2.29
LIF 3.62 1.00 2.53 2.34 1.25 1.74
CCND2 29.74 0.80 2.03 2.20 7.82 1.72 PC
SERPINB5 15.92 1.43 1.55 2.19 0.11 0.93 PC
SPRY2 8.61 0.60 3.08 2.18 6.63 2.29 PC
GJB2 8.08 1.28 1.63 2.12 0.64 0.36
RBBP8 7.05 3.01 0.34 2.03 2.12 0.04
SMAD3 8.00 0.74 2.27 2.03 3.59 1.02 PC
DKK1 11.38 0.02 2.85 1.89 5.81 2.48 PC
DAB2IP 3.23 2.31 0.18 1.85 0.32 1.47 PC
ANXA1 31.55 0.96 1.69 1.84 0.73 0.03 PC
PML 3.00 2.49 0.27 1.81 0.91 0.25 PC
PHLDA2 3.32 1.43 0.71 1.72 1.98 1.05
DKK3 10.43 1.42 0.83 1.66 2.28 2.93 PC
NFKB2 3.52 1.96 0.33 1.64 0.09 2.21
RND3 11.92 0.43 1.84 1.58 3.10 2.19 PC
MET 26.96 0.47 1.61 1.52 6.06 0.82 PC
Cbio MSKCC resource. Boldface: Prostate TSG contained in 903 hypermethylated gene list. Shaded rows: TSG reported in prostate cancer.
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Figure 4. Prostate cancer–related gene deregulation shows opposite acH2A.Z/H2A.Z promoter enrichment profiles. (A) Microarray hybridization
signals for mRNA expression levels in LNCaP (red) and PrEC (green) of three example oncogenes: KLK2; C15orf21; and ERBB3; and three example TSGs:
CAV1, CAV2, and RND3 (top). (Bottom) UCSC Genome Browser tracks for DNA methylation (MBDCap.seq, red background), H3K27me3 (blue back-
ground), H2A.Z, acH2A.Z and acH2A.Z/H2A.Z ChIP-on-chip profiles. SssI (violet tracks): fully methylated positive control DNA. (B) Validation of tiling
array, gene expression, and ChIP-on-chip data for H2A.Z, acH2A.Z, and acH2A.Z/H2A.Z using real-time qPCR. Relative mRNA levels normalized using
GAPDH. For ChIP data, all samples were normalized with their corresponding Input chromatin and represented as 2-DCT (see Methods). H2A.Z and acHA.Z
data are representative examples of three independent experiments; acH2A.Z/H2A.Z is represented as fold change of LNCaP relative to PrEC (mean of the
fold change 6SEM). Note, for the ERBB3 gene, there is a gain of the relative acetylation of H2A.Z (acH2A.Z/H2A.Z fold enrichment) in LNCaP cells due to
the relative depletion of total H2A.Z in this region (H2A.Z IP). Abbreviations, colors, and symbols are the same as in Figure 3.
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Figure 5. Acetylation of H2A.Z correlates with gene activation in prostate cancer. (A) LNCaP cells were either untreated () or treated (+) with Trichostatin A
(TSA) at 100 nM for 48 h. Gene expression levels of CAV1 and CAV2 (A) or LIMCH1, KLK2, and KLK3 (B) genes were measured by RT–qPCR, and acH2A.Z levels at
TSSs were measured by ChIP qPCR. Relative mRNA levels were normalized using ALAS1. A concordant increase in acH2A.Z and gene activation, after TSA treatment
was observed for all genes. (C ) LNCaP cells were either untreated () or treated (+) with Anacardic Acid (AA) at 90 mM for 48 h. Gene expression levels of C15orf21,
KLK2, and KLK3 genes were measured by RT–qPCR, and acH2A.Z levels at the TSS were measured by ChIP qPCR. Relative mRNA levels were normalized using
ALAS1. A concordant decrease in acH2A.Z and gene repression, after AA treatment, was observed. (D) (Left) Microarray hybridization signals for mRNA expression
levels in PrEC (green), LNCaP (red), DU-145 (orange), and PC-3 (yellow) of five gene examples KLK2, C15orf21, CAV2, CAV1, and RND3. (Right) acH2A.Z ChIP
qPCR at the promoter region of KLK2, C15orf21, CAV2, CAV1, and RND3 as per Figure 4. Gray background in the bottom panel highlights an arbitrary threshold for
the minimum acH2A.Z signal associated with gene activation. Acetylation of H2A.Z correlates with gene activation in all gene examples.
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a bimodal pattern of H2A.Z occupancy across the TSSs of both basal/
poised and expressed genes, whereas uniform distribution of H2A.Z
occurs across the gene promoters of inactive genes. We show for the
first time that it is acetylation of H2A.Z-occupied nucleosomes at
TSSs that potentially drives active gene expression in normal cells,
and deacetylation of H2AZ that drives gene repression in cancer
cells, rather than a change in H2A.Z occupancy alone.
Acetylation of H2A.Z around the TSS is a mark of active genes
Our results support previous findings that show high enrichment of
H2A.Z at promoter regions (Barski et al. 2007), spanning at least3 to
+3 nucleosomes of actively transcribed genes in the human genome
(Schones et al. 2008). However, our data also suggest that the region
upstream of the TSS, which is more enriched in H2A.Z, might con-
tribute to gene activity by maintaining chromatin accessibility for
transcription-factor binding and RNA poll II recruitment (Hardy et al.
2009). Indeed, the enrichment of H2AZ nucleosomes at promoters
has been shown to increase the nucleosome turnover rate in yeast
(Dion et al. 2007), suggesting a more mobile nature of H2A.Z-con-
taining nucleosomes. It has also been proposed that H2A.Z is asso-
ciated with chromatin that has architecture suitable for either acti-
vation or repression of local genes (Guillemette and Gaudreau 2006).
We show that the transcriptional state appears to be determined by
a specific post-translational modification to H2A.Z. It has previously
been shown that mammalian H2A.Z can be acetylated or mono-
ubiquitylated at specific lysines (Sarcinella et al. 2007; Ishibashi et al.
2009). Our results demonstrate that H2A.Z is only hyperacetylated
surrounding the TSSs of actively transcribed genes and not in genes
poised or lowly transcribed. In addition, we observe a gain of H2A.Z
acetylation at TSSs after histone deacetylation (HDAC) drug-induced
gene activation, and conversely, a loss of acH2A.Z after histone ace-
tyltransferase (HAT) drug-induced gene repression, suggesting a
functional link between these two events. Acetylation of H2A.Z is
also reported to be associated with active gene promoters in other
organisms, and this modification is thought to be important for the
conformational change of nucleosomes (Ishibashi et al. 2009).
Silent genes harbor both H2A and H2A.Z across
the entire promoter
Interestingly, some studies have reported H2A.Z to be absent from
inactive genes (Bruce et al. 2005), and other studies have found H2A.Z
to be involved in negative regulation of transcription reporting high
levels at heterochromatic regions (Hardy et al. 2009). We find in
human cells that inactive genes, in contrast to active or lowly tran-
scribed genes, contain both H2A and H2A.Z distributed evenly across
the whole promoter. It is unclear whether H2A.Z and H2A occur as
homotypic nucleosomes randomly distributed across repressed pro-
moters, or whether both histones are contained in the same nucle-
osome to constitute heterotypic nucleosomes (Chakravarthy et al.
2004; Viens et al. 2006; Ishibashi et al. 2009). A previous study
showed that heterotypic coexistence of H2A and H2A.Z in a nucle-
osome did not have significant effects on its stability or its confor-
mation, but the coexistence of acetylation marks could mediate
destabilization of chromatin (Ishibashi et al. 2009). Therefore, a
combination of histone post-translational modifications within
heterotypic nucleosomes would potentially affect its stability,
leading to alterations in gene transcription. However, Weber et al.
(2010) reported that structural differences between heterotypic and
homotypic nucleosomes contributed to the localization and func-
tion of H2AZ in Drosophilia. Our results suggest that this may also be
conserved in mammals, where H2A–H2A.Z replacement only takes
place in actively transcribed genes, while hybrid nucleosomes are
the predominant form in lowly expressed genes, generating another
level of structural and functional heterogeneity in chromatin. ChIP–
reChIP assays experiments, however, are needed to further dem-
onstrate the presence of heterotypic nucleosomes.
Deregulation of gene expression in cancer accompanies
remodeling of the acH2A.Z/H2A.Z promoter landscape
We show for the first time that there is an alteration in the acety-
lation pattern of H2A.Z across the TSS of genes in prostate cancer
cells, and this is strongly associated with changes in gene expres-
sion. Down-regulated genes exhibit a gain of hypoacetylated H2A.Z
at proximal promoters (Fig. 8A). However, it is still unresolved
whether H2A.Z is deacetylated by HDACs or whether there is his-
tone exchange (Lu et al. 2009). It is interesting to note that down-
regulated genes still contain H2A.Z at their promoters, suggesting
that rather than being permanently silenced, these genes are po-
tentially capable of reactivation. Conversely, activated genes in the
cancer cells gain hyperacetylated H2A.Z (Fig. 8B), but again, it is
unclear whether this is a result of active acetylation by a histone
acetyltransferase (HAT) prior to, or during transcription (Millar et al.
2006), or due to nucleosome exchange with acetylated H2A.Z
(Doyon and Cote 2004; Mizuguchi et al. 2004).
In particular, we have found that H2A.Z reorganization was
common and occurred in a significant number of genes involved in
development and progression of prostate cancer (Tables 1, 2). In-
terestingly, overexpression of H2A.Z promotes cell proliferation in
breast cancer (Gevry et al. 2009a,b), and increased gene expression
of H2AFZ has been reported in several major types of malignancies
(Dunican et al. 2002), suggesting that in the light of our new data
this may be due to an increase in the available H2AZ for acetylation.
In contrast, a progressive depletion of H2A.Z around TSSs during
murine lymphomagenesis has been described correlating with a loss
of gene expression (Rhodes et al. 2004; Zucchi et al. 2004; Hua et al.
2008; Conerly et al. 2010). Our work suggests a new mechanism for
gene deregulation in cancer through changes in H2A.Z occupancy
Figure 6. Anticorrelation between DNA methylation and H2A.Z or acH2A.Z in human prostate cancer. (A) Significance plots compared H2A.Z,
acH2A.Z, and acH2A.Z/H2AZ with DNA methylation status in PrEC (top) and LNCaP cells (bottom). The average signal of corresponding ChIP-on-chip data
(y-axis: signal intensity) of highly methylated genes (>80% relative to the SssI) is represented as a red line along the gene promoter (x-axis), whereas lowly
methylated genes are represented as a black line (<20% relative to the SssI). Blue line represents randomly selected genes from the pool of neither high nor
lowly methylated; light-blue background covers the 95% confidence interval of the data. (B) Significance plots for the average signal of H2A.Z, acH2A.Z,
and acH2A.Z/H2A.Z along gene promoters that change in expression and DNA methylation in LNCaP compared with PrEC (LNCaP-PrEC). Red line
corresponds to DNA hypermethylated ($2-fold) and down-regulated ($1.5 t-stats) genes; black line represents DNA hypomethylated (#2-fold) and
down-regulated genes (#1.5 t-stats) in LNCaP-PrEC. (C ) Three gene examples (RND3, MKRN3, and LIMCH1) that show change in acH2A.Z/H2A.Z
promoter enrichment and DNA methylation in prostate cancer. ChIP qPCR of H2A.Z and acH2A.Z confirms a gain of acH2A.Z/H2A.Z. DNA methylation
using Sequenom MALDI-TOF analysis of genomic DNA from the promoter region was calculated by averaging the ratios obtained from each CpG site from
both LNCaP and PrEC. CpG sites correspond to the same regions analyzed for H2A.Z and acH2A.Z occupancy.
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in promoters and changes in H2A.Z acetylation states, and that
acetylation of H2A.Z could be a plausible target for prostate cancer
management (Rangasamy 2010).
Acetylation of H2A.Z is anticorrelated with both DNA
methylation and K27me3, and is prevalent in gene
deregulation during carcinogenesis
The mutual exclusion between DNA methylation and H2A.Z de-
position has been recently reported in mice (Conerly et al. 2010).
Here, we find that it is primarily the acetylation of H2A.Z that is
anticorrelated with DNA methylation. Moreover, we find that
acH2A.Z anticorrelates with the presence of the repressive poly-
comb H3K27me3 mark. In fact, we demonstrate that alteration of
H2A.Z acetylation in prostate cancer is associated with an inverse
change in DNA methylation and/or H3K27me3 status. In embry-
onic stem cells, H2A.Z and polycomb protein occupancy is in-
terdependent at promoters of developmentally important genes;
however, this is not maintained in lineage-committed cells
(Creyghton et al. 2008). Our data suggest the opposite pattern
in prostate cells, where, in particular, the presence of acH2A.Z
strongly anticorrelates with K27me3 mark.
Conclusion
We show that in mammals modification of H2A.Z by acetylation is
the primary mark that mutually excludes DNA methylation and/or
H3K27me3, rather than H2A.Z occupancy alone. We propose that
acH2A.Z contributes to unstable nucleosomes, and in concert with
DNA demethylation and/or loss of K27me3 promotes an unstable
region to allow the access of the transcription machinery to acti-
vate gene expression. Conversely, gene repression is associated
with deacetylation of H2A.Z at transcriptional start sites in com-
Figure 7. Anticorrelation between H3K27me3 and H2A.Z or acH2A.Z promoter presence in prostate cancer. (A) Significance plots of H3K27me3 signal
comparing H2A.Z, acH2A.Z, and acH2A.Z/H2A.Z along gene promoters in genes sorted by high (red line) or low (black line) levels of H2A.Z, acH2A.Z, and
acH2A.Z/H2A.Z in PrEC (top) and LNCaP (bottom). The selection criteria of H2A.Z, acH2A.Z, and acH2A.Z/H2A.Z for high levels were t-stats $ 1.5 (red
line), and t-stats # 1.5 for low levels (black line), as explained in the Supplemental Methods. (B) Significance plots of changes in the H3K27me3 signal
(LNCaP-PrEC) along gene promoters in genes sorted by gain (t-stats $ 1.5, red line) or loss (t-stats # 1.5, black line) of H2A.Z, acH2A.Z, and acH2A.Z/
H2A.Z in LNCaP-PrEC. (C ) ChIP qPCR using H3K27me3 antibody was performed to validate the anticorrelation in four different prostate cancer–related
genes: CAV1 and RND3 (top) and KLK2 and LIMCH1 (bottom). See Figure 4 for validation of H2A.Z, acH2A.Z levels.
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bination with promoter DNA hypermethylation and/or gain of
H3K27me3. Further research is required to investigate what drives
the prescriptive pattern of H2A.Z localization and what initiates
H2A.Z acetylation associated with gene transcription in normal
cells and its deregulation in cancer.
Methods
Cell lines and culture conditions
LNCaP, DU-145, and PC-3 prostate cancer cells and two inde-
pendent cultures of normal prostate epithelial cells PrEC cells
(Cambrex Bio Science Cat. No. CC-2555: PrEC1 and PrEC2; tissue
acquisition nos. #13683 and #13639) were cultured as described
previously (Coolen et al. 2010). LNCaP cells were treated with
Trichostatin A (TSA; Sigma) at 100 nM for 48 h, adding fresh TSA
every 24 h. LNCaP cells were also treated with Anacardic Acid
(6-pentadecylsalicylic acid, AA; Calbiochem) at 90 mM for 48 h.
The untreated controls were mock treated with the equivalent
amount of the vehicle used to dissolve the drugs, 100% ethanol for
the TSA experiments, and 100% DMSO for AA treatment.
RNA isolation and gene expression array analysis
RNA was extracted from cell lines using TRIzol reagent (Invitrogen)
and Affymetrix GeneChip HuGene 1.0 ST were performed as de-
scribed previously (Coolen et al. 2010). Analysis of expression ar-
ray data is described in the Supplemental Methods.
Chromatin immunoprecipitation (ChIP) assays
The ChIP assays for acetylated-histone H3 (H3K9ac), K4 trimethyl-
histone H3 (H4K4me3), and K27 trimethyl-histone H3 (H3K27me3)
were performed previously (Coolen et al. 2010). H2A, H2A.Z, and
acetylated H2A.Z (acH2A.Z) ChIP assays were carried out ac-
cording to Coolen et al. (2010) using antibodies specific for H2A.Z
(Abcam#ab4174), H3 (Abcam#: ab1791), H2A.Z acetyl K4+K7+K11
(Abcam#ab18262), and H2A (Abcam#ab18255). Note H2A.Z
(Abcam#ab4174) antibody recognizes both acetylated and deace-
tylated forms, whereas H2A.Z acetyl K4+K7+K11 (Abcam#ab18262)
only recognizes acH2AZ. See the Supplemental Methods for a de-
tailed explanation.
Whole-genome amplification and promoter array analyses
Immunoprecipitated DNA and input DNA from ChIP was am-
plified with GenomePlex Complete Whole Genome Amplifica-
tion (WGA) Kit (Sigma Cat. No.#WGA2) according to the man-
ufacturer’s instructions and hybridized to Affymetrix GeneChip
Human Promoter 1.0R Array as described previously (Coolen
et al. 2010). Analysis of arrays was performed as described in the
Supplemental Methods using two independent IPs per biological
sample, where the correlation coefficients were above 0.89. En-
richment of ChIP signals was visualized using the UCSC Genome
Browser software (http://genome.ucsc.edu/).
Methylation profiling by MBD2 capture
The MethylMiner Methylated DNA Enrichment Kit (Invitrogen)
was used to isolate methylated DNA from LNCaP and PrEC cell
lines according to Nair et al. (2011) CpG Genome universal
methylated DNA obtained from Millipore (Cat# 57821) was used
for fully methylated positive control DNA. Bound methylated
DNA was eluted in a single fraction using High Salt Elution
Buffer (Nair et al. 2011) and resuspended in 60 uL of H2O. Ten
nanograms of MBD captured DNA were used for library prepa-
ration, and Illumina GAII sequencing was performed at the
Ramaciotti Center, UNSW, Sydney to generate a 36-bp read
length. The 36-bp reads were mapped to the hg18 reference ge-
nome using Bowtie (Langmead et al. 2009), with up to three
mismatches. Reads that mapped more than once to a single ge-
nomic location were filtered. With one lane of Illumina Genome
Analyzer sequencing with 36-base single end reads, we were able
to uniquely map 10,491,054 and 10,139,044 for PrEC and
LNCaP, respectively.
Quantitative real-time RT–PCR validation analysis
of gene expression
RT–PCR analysis was performed as described previously (Frigola
et al. 2006). Primers used for RT–PCR amplification (qPCR) are
listed in Supplemental Table 5 and used as described previously for
CAV1 and CAV2 (Coolen et al. 2010). Reactions were performed in
triplicate, and standard deviation calculated using the 2-DDCt
method (RQ) (Livak and Schmittgen 2001) (Applied Biosystems
Figure 8. Model of gene transcriptional regulation dependent on H2A.Z
occupancy and its acetylated state in prostate cancer. (A) In a normal cell,
genes that are actively transcribed exhibit a bimodal distribution of at least
three acetylated H2A.Z nucleosomes plus and minus the TSS. In cancer,
some inactivated genes (including TSG), undergo epigenetic change across
the promoter that includes deacetylation of H2A.Z nucleosomes, either
through active deacetylation or exchange of a H2A.Z nucleosome (de-
picted as ‘‘?’’). (B) In contrast, in a normal cell inactive genes contain a mix
of H2A and H2A.Z nucleosomes across the entire promoter (H2A/H2A.Z
nucleosomes). The apparent mix of H2A or H2A.Z–nucleosomes could
be heterotypic nucleosomes containing one H2A dimer and one H2A.Z
dimer, or H2A.Z and H2A homotypic nucleosomes deposited alternatively
across the promoter. In a cancer cell there is a general loss of H2A.Z nu-
cleosomes, together with a gain of acH2A.Z nucleosomes plus and minus
three or more nucleosomes around the TSS, either through active acety-
lation or exchange of a H2A.Z nucleosome (depicted as ‘‘?’’), resulting in an
overexpression of these genes (e.g., oncogenes).
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User Bulletin N°2 [P/N 4303859]) to calculate the relative gene
expression between LNCaP and PrEC cells. The data are presented
as the fold change in mRNA gene expression of each gene nor-
malized to either GAPDH or ALAS1 as endogenous reference gene
and relative to the normal cell line PrEC
Validation of ChIP–chip arrays by quantitative real-time
PCR analysis
The amount of target immunoprecipitated was measured by qPCR
using the ABI Prism 7900HT Sequence Detection System as de-
scribed previously (Coolen et al. 2010). The amplification primers
used for validation are listed in Supplemental Table 5. For each
sample, the amount of material that was immunopreciptated rela-
tive to the amount of input chromatin was calculated according to
Coolen et al. (2010). Experiments were repeated at least three times.
DNA methylation analysis using Sequenom analysis
DNA was extracted from cell lines using DNeasy Blood and Tissue
Kit (QIAGEN) according to the manufacturer’s instructions.
Bisulphite treatment was carried out as previously described (Clark
et al. 2006). As controls for the methylation analysis, whole-ge-
nome-amplified (WGA) DNA (0% methylated) and M.SssI-treated
DNA (100% methylated) (Millipore#S7821) were bisulphite treated
in parallel. Sequenom methylation analysis was performed as de-
scribed previously (Coolen et al. 2007). The results were analyzed by
the EpiTYPER software V 1.0 and methylation ratios were calculated
as described in Nair et al. (2011).
Computational analyses for gene expression, tiling arrays,
and MBDCap sequencing data comparisons
Heatmaps and line plots
For correlation analyses between gene expression and H2A, H2A.Z,
acH2A.Z, H3K9ac, H3K4me3, and H3K27me3 binding, the ‘‘bin-
Plots’’ procedure from the Repitools R package (Statham et al.
2010) was used. Briefly, the MAT-normalized tiling array data was
smoothed using a trimmed mean over windows of 600 bases that
contained 10 or more probes. Heatmaps or line plots were gener-
ated as summaries of these smoothed values over the regions of
promoters (7500 bp upstream to 2450 bp downstream) where data
is available. Genes were grouped according to summarized gene
expression levels (see Supplemental Methods) and median-
smoothed tiling array signal was calculated for each group and
each region of the promoter.
Box plots and gene set tests
Box plots showing the distribution of t-statistics (See Supplemental
Methods) for changes in H2A.Z, acH2A.Z, and acH2A.Z/H2A.Z
(between LNCaP and PrEC) were made to interrogate the cross-talk
between acH2A.Z and H2A.Z in deregulated genes. The top 10% of
down-regulated genes that have a acH2A.Z/H2A.Z t-stats value
#1.5 were selected as the group of ‘‘down-regulated genes + loss
of acH2A.Z/H2A.Z’’ (479 genes in total); for ‘‘up-regulated genes +
gain of acH2A.Z/H2A.Z’’, the top 10% of up-regulated genes that
have a acH2A.Z/H2A.Z t-stats value $1.5 were extracted (545 genes
in total). For testing the changes in signal for gene sets as a whole,
the null distribution contains t-statistics of all genes that did not
belong to either the down-regulated category or the up-regulated
category. The P-values of the significance of differences between
groups of genes were obtained with the ‘‘geneSetTest’’ in the R
limma package (Smyth 2004).
Gene set profile plots
Plots of tiling array signal (H2A.Z, acH2A.Z, acH2A.Z/H2A.Z, and
K27Me3) and MBDCap across the promoter summarized over gene
sets of interest, so-called gene-set profile plots, were created using
the ‘‘significancePlots’’ procedure in the Repitools R package
(Statham et al. 2010). Briefly, the smoothed tiling array signal is
summarized for probes at each region of the promoter. To create
a basis for comparison, many random gene sets (of the size of the
biggest gene set) are taken and 2.5%-ile, 50%-ile (median), and
97.5%-iles of signal are plotted. The gene sets selected are
explained in the Supplemental Methods.
Data access
Data from this study have been submitted to the NCBI Gene Ex-
pression Omnibus (http://ncbi.nlm.nih.gov/geo) under SuperSeries
accession numbers GSE25914, GSE24546, and GSE19726.
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